<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="cpt1a" content-type="chapter" from-where="body" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">gene</book-id>
    <book-title-group>
      <book-title>GeneReviews<sup>&#x000ae;</sup></book-title>
    </book-title-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Adam</surname>
          <given-names>Margaret P</given-names>
        </name>
        <role>Editor-in-Chief</role>
      </contrib>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ardinger</surname>
          <given-names>Holly H</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Pagon</surname>
          <given-names>Roberta A</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Wallace</surname>
          <given-names>Stephanie E</given-names>
        </name>
      </contrib>
      <role>Senior Editors</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Bean</surname>
          <given-names>Lora JH</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Mefford</surname>
          <given-names>Heather C</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Stephens</surname>
          <given-names>Karen</given-names>
        </name>
      </contrib>
      <role>Molecular Genetics</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Amemiya</surname>
          <given-names>Anne</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ledbetter</surname>
          <given-names>Nikki</given-names>
        </name>
      </contrib>
      <role>Genetic Counseling</role>
    </contrib-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>1993</year>
    </pub-date>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>2017</year>
    </pub-date>
    <issn>2372-0697</issn>
    <publisher>
      <publisher-name>University of Washington, Seattle</publisher-name>
      <publisher-loc>Seattle (WA)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 1993-2017, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved.</copyright-statement>
      <copyright-year>2017</copyright-year>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK138602/">
        <license-p>GeneReviews&#x000ae; chapters are owned by the University of Washington. Permission is hereby granted to reproduce, distribute, and translate copies of content materials for noncommercial research purposes only, provided that (i) credit for source (<ext-link ext-link-type="uri" xlink:href="http://www.genereviews.org/">http://www.genereviews.org/</ext-link>) and copyright (&#x000a9; 1993-2017 University of Washington) are included with each copy; (ii) a link to the original material is provided whenever the material is published elsewhere on the Web; and (iii) reproducers, distributors, and/or translators comply with the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>. No further modifications are allowed. For clarity, excerpts of GeneReviews chapters for use in lab reports and clinic notes are a permitted use.</license-p>
        <license-p>For more information, see the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>.</license-p>
        <license-p>For questions regarding permissions or whether a specified use is allowed, contact: <email>admasst@uw.edu</email>.</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Genetics</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Medicine</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Diseases</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="ednotes">
      <p content-type="genetic_counseling">
<italic toggle="yes">Genetic counseling is the process of
providing individuals and families with information on the nature, inheritance,
and implications of genetic disorders to help them make informed medical and
personal decisions. The following section deals with genetic risk assessment and
the use of family history and genetic testing to clarify genetic status for
family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with
a genetics professional</italic>. &#x02014;ED.</p>
      <p content-type="resources">
<italic toggle="yes">GeneReviews staff has selected the following disease-specific and/or
umbrella support organizations and/or registries for the benefit of individuals
with this disorder and their families. GeneReviews is not responsible for the
information provided by other organizations. For information on selection
criteria, click <related-object source-id="gene" document-id="app4">here</related-object>.</italic></p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <book-part-id book-part-id-type="pmcid">cpt1a</book-part-id>
      <title-group>
        <title>Carnitine Palmitoyltransferase 1A Deficiency</title>
        <alt-title alt-title-type="alt-title">Synonyms: CPT1A Deficiency, Hepatic Carnitine Palmitoyltransferase 1 Deficiency</alt-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Bennett</surname>
            <given-names>Michael J</given-names>
          </name>
          <degrees>PhD, FRCPath, DABCC</degrees>
          <aff>Professor of Pathology and Laboratory Medicine<break/>University of Pennsylvania Perelman School of Medicine<break/>Evelyn Willing Bromley Endowed Chair, Clinical Laboratories and Pathology<break/>Children's Hospital of Philadelphia<break/>Philadelphia, Pennsylvania</aff>
          <email>bennettmi@email.chop.edu</email>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Santani</surname>
            <given-names>Avni B</given-names>
          </name>
          <degrees>PhD, FACMG</degrees>
          <aff>Assistant Professor of Clinical Pathology and Laboratory Medicine<break/>University of Pennsylvania Perelman School of Medicine<break/>Director, Division of Genomic Diagnostics<break/>Children&#x02019;s Hospital of Philadelphia<break/>Philadelphia, Pennsylvania</aff>
          <email>santani@email.chop.edu</email>
        </contrib>
      </contrib-group>
      <pub-history>
        <date iso-8601-date="2005-07-27" date-type="created">
          <day>27</day>
          <month>7</month>
          <year>2005</year>
        </date>
        <date iso-8601-date="2016-03-17" date-type="updated">
          <day>17</day>
          <month>3</month>
          <year>2016</year>
        </date>
        <date iso-8601-date="2009-03-24" date-type="revised">
          <day>24</day>
          <month>3</month>
          <year>2009</year>
        </date>
      </pub-history>
      <related-object link-type="parent-book-link" source-id="gene">GeneReviews<sup>&#x000ae;</sup></related-object>
      <related-object link-type="previous-part-link" source-id="gene" document-id="carney" document-type="chapter">Carney Complex</related-object>
      <related-object link-type="next-part-link" source-id="gene" document-id="cpt2" document-type="chapter">Carnitine Palmitoyltransferase II Deficiency</related-object>
      <abstract id="cpt1a.Summary">
        <title>Summary</title>
        <sec>
          <title>Clinical characteristics</title>
          <p>Carnitine palmitoyltransferase 1A (CPT1A) deficiency is a disorder of long-chain fatty acid oxidation. Clinical manifestations usually occur in an individual with a concurrent febrile or gastrointestinal illness when energy demands are increased; onset of symptoms is usually rapid. The recognized phenotypes are: acute fatty liver of pregnancy, in which the fetus has biallelic pathogenic variants in <italic toggle="yes">CPT1A</italic> that causes CPT1A deficiency; and hepatic encephalopathy, in which individuals (typically children) present with hypoketotic hypoglycemia and sudden onset of liver failure. Individuals with hepatic encephalopathy typically present with hypoglycemia, absent or low levels of ketones, and elevated serum concentrations of liver transaminases, ammonia, and total carnitine. Between episodes of hepatic encephalopathy, individuals appear developmentally and cognitively normal unless previous metabolic decompensation has resulted in neurologic damage.</p>
        </sec>
        <sec>
          <title>Diagnosis</title>
          <p>The diagnosis of CPT1A is established in a proband by the detection of biallelic pathogenic variants in <italic toggle="yes">CPT1A</italic> on molecular genetic testing or diminished carnitine palmitoyltransferase 1 (CPT 1) enzyme activity on cultured skin fibroblasts when molecular genetic testing is not definitive. Residual enzyme activity is 1%-5% in most individuals with CPT1A deficiency.</p>
        </sec>
        <sec>
          <title>Management</title>
          <p><italic toggle="yes">Treatment of manifestations</italic>: Prompt treatment of hypoglycemia with intravenous fluid containing 10% dextrose; the dextrose infusion should be maintained past the time that the blood glucose concentration has normalized in order to replete hepatic glycogen stores. Affected individuals, parents/guardians, and health care providers need to have readily available emergency treatment protocols for catastrophic metabolic crises.</p>
          <p><italic toggle="yes">Prevention of primary manifestations:</italic> To prevent hypoglycemia, infants should eat frequently during the day and have cornstarch continuously at night; fasting should not last more than 12 hours during illness, surgery, or medical procedures; adults need a high-carbohydrate, low-fat diet to provide a constant supply of carbohydrate energy and medium-chain triglycerides to provide approximately one third of total calories (C6-C10 fatty acids do not require the carnitine shuttle for entry into the mitochondrion).</p>
          <p><italic toggle="yes">Prevention of secondary complications:</italic> Prevention of hypoglycemia reduces the risk for related neurologic damage.</p>
          <p><italic toggle="yes">Surveillance:</italic> Individuals with CPT1A deficiency should have testing of liver enzymes (AST, ALT, alkaline phosphatase) and liver function (including PT and PTT) at clinic appointments, even when asymptomatic, and during periods of reduced caloric intake and febrile illness.</p>
          <p><italic toggle="yes">Agents/circumstances to avoid:</italic> Prolonged fasting; potentially hepatotoxic agents such as valproate and salicylate.</p>
          <p><italic toggle="yes">Evaluation of relatives at risk:</italic> Regardless of age, each sib of a proband should be evaluated for CPT1A deficiency by either molecular genetic testing (if both pathogenic variants have been identified in the proband) or by enzyme analysis in cultured skin fibroblasts.</p>
          <p><italic toggle="yes">Pregnancy management:</italic> Heterozygous pregnant women should be monitored for acute fatty liver of pregnancy.</p>
        </sec>
        <sec>
          <title>Genetic counseling</title>
          <p>CPT1A deficiency is inherited in an autosomal recessive manner. Heterozygotes (carriers) are asymptomatic, although heterozygous pregnant women may be at risk of developing acute fatty liver of pregnancy if the fetus has CPT1A deficiency. At conception, each sib of an affected individual has a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier. Carrier testing for at-risk family members and prenatal diagnosis for pregnancies at increased risk are possible by biochemical testing if the enzyme defect has been confirmed in an affected family member or by molecular genetic testing if both pathogenic variants have been identified in an affected family member.</p>
        </sec>
      </abstract>
    </book-part-meta>
    <body>
      <sec id="cpt1a.Diagnosis">
        <title>Diagnosis</title>
        <sec id="cpt1a.Suggestive_Findings">
          <title>Suggestive Findings</title>
          <p>Carnitine palmitoyltransferase IA (CPT IA) deficiency <bold>should be suspected</bold> in an individual with the following prenatal history, newborn screening results, postnatal clinical features, and supportive laboratory findings:</p>
          <p>
            <bold>Prenatal history</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p><bold>Maternal acute fatty liver of pregnancy.</bold> CPT1A deficiency in a fetus can lead to the following maternal findings during pregnancy:</p>
              <list list-type="bullet">
                <list-item>
                  <p>Hypoglycemia</p>
                </list-item>
                <list-item>
                  <p>Abnormal liver enzymes</p>
                </list-item>
                <list-item>
                  <p>Hyperammonemia</p>
                </list-item>
                <list-item>
                  <p>Abnormal hepatic synthetic function resulting in bleeding diathesis</p>
                </list-item>
              </list>
            </list-item>
          </list>
          <p>
            <bold>Newborn screening results</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>Increased ratio of free carnitine to the sum of C16:0 (palmitoylcarnitine) plus C18 acylcarnitines ( C18:1, oleic acid and C18:2 linoleic acid) on a newborn screen blood spot [<xref ref-type="bibr" rid="cpt1a.REF.fingerhut.2001.1763">Fingerhut et al 2001</xref>, <xref ref-type="bibr" rid="cpt1a.REF.sim.2001.51">Sim et al 2001</xref>]. See <named-content content-type="highlight-1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.acmg.net/StaticContent/ACT/C0_C16-C18.pdf">ACMG ACT Sheet</ext-link></named-content>.</p>
            </list-item>
          </list>
          <p>
            <bold>Postnatal clinical findings</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>Hepatic encephalopathy (similar to that seen in Reye syndrome) precipitated by fasting or fever (see <bold>Supportive laboratory findings</bold>)</p>
            </list-item>
            <list-item>
              <p>Rapid onset of symptoms in association with a relatively common infectious disease, such as a febrile or gastrointestinal illness</p>
            </list-item>
          </list>
          <p>
            <bold>Supportive laboratory findings</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p><bold>Hypoketotic hypoglycemia</bold>, defined as low blood glucose concentration (&#x0003c;40 mg/dL) in the absence of ketone bodies in the urine</p>
            </list-item>
            <list-item>
              <p><bold>Elevated liver enzymes.</bold> AST and ALT that are two- to tenfold the upper limit of normal</p>
            </list-item>
            <list-item>
              <p><bold>Hyperammonemia.</bold> Plasma ammonia concentrations usually 100-500 &#x000b5;mol/L (normal: &#x0003c;70 &#x000b5;mol/L)</p>
            </list-item>
            <list-item>
              <p><bold>Elevated total serum carnitine</bold> in the range of 70-170 &#x000b5;mol/L (normal total serum carnitine: 25-69 &#x000b5;mol/L). The elevation of total carnitine and hypoketotic hypoglycemia should increase suspicion specifically for CPT1A deficiency.</p>
            </list-item>
            <list-item>
              <p><bold>Elevated ratio of C0/C16+C18 acylcarnitines.</bold> CPT1A deficiency is charaterized by marked reduction in the synthesis of all acylcarnitine species and increased levels of free carnitine (C0) (see <named-content content-type="highlight-1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.acmg.net/StaticContent/ACT/C0_C16-C18.pdf">ACMG ACT Sheet</ext-link></named-content>).</p>
            </list-item>
            <list-item>
              <p><bold>Urine organic acids</bold> that demonstrate elevated dodecanedioic acid during acute crisis and for several days following [<xref ref-type="bibr" rid="cpt1a.REF.korman.2005.337">Korman et al 2005</xref>]. The authors have also observed C12 dicarboxylic acid elevation during acute crisis in individuals subsequently diagnosed with CPT1A deficiency [Bennett, personal unpublished observation].</p>
            </list-item>
          </list>
        </sec>
        <sec id="cpt1a.Establishing_the_Diagnosis">
          <title>Establishing the Diagnosis</title>
          <p>The diagnosis of CPT1A <bold>is established</bold> in a proband by the detection of biallelic pathogenic variants in <italic toggle="yes">CPT1A</italic> on molecular genetic testing (see <xref ref-type="table" rid="cpt1a.T.molecular_genetic_testing_used_i">Table 1</xref>) or diminished carnitine palmitoyltransferase 1 (CPT 1) enzyme activity measured on cultured skin fibroblasts when molecular genetic testing is not definitive.</p>
          <p><bold>Molecular genetic testing</bold> approaches can include <bold>single-gene testing</bold> and use of a <bold>multi-gene panel.</bold></p>
          <list list-type="bullet">
            <list-item>
              <p><bold>Single-gene testing.</bold> Sequence analysis of <italic toggle="yes">CPT1A</italic> is performed first, followed by gene-targeted deletion/duplication analysis if only one or no pathogenic variant is found. Note: Targeted analysis may be considered first for the following pathogenic variants:</p>
              <list list-type="bullet">
                <list-item>
                  <p><xref ref-type="table" rid="cpt1a.T.selected_cpt1a_pathogenic_alleli">p.Pro479Leu</xref> in populations with a very high frequency of this allele, including: infants who test positive for CPT1A deficiency in the state of Alaska newborn screening program, the Canadian First Nations population in Nunavut (i.e., Inuit) [<xref ref-type="bibr" rid="cpt1a.REF.collins.2010.200">Collins et al 2010</xref>], the Greenland Inuit [<xref ref-type="bibr" rid="cpt1a.REF.rajakumar.2009.1223">Rajakumar et al 2009</xref>], and Siberians [<xref ref-type="bibr" rid="cpt1a.REF.clemente.2014.584">Clemente et al 2014</xref>]. Most affected individuals in these populations are homozygous for this variant [<xref ref-type="bibr" rid="cpt1a.REF.park.2006.1090">Park et al 2006</xref>].</p>
                </list-item>
                <list-item>
                  <p><xref ref-type="table" rid="cpt1a.T.selected_cpt1a_pathogenic_alleli">p.Gly710Glu</xref>, which is common in the Hutterite population [<xref ref-type="bibr" rid="cpt1a.REF.prasad.2001.55">Prasad et al 2001</xref>]</p>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p><bold>A multi-gene panel</bold> that includes <italic toggle="yes">CPT1A</italic> and other genes of interest (see <xref ref-type="sec" rid="cpt1a.Differential_Diagnosis">Differential Diagnosis</xref>) may also be considered. Note: (1) The genes included in the panel and the diagnostic sensitivity of the testing used for each gene vary by laboratory and over time. (2) Commercially offered multi-gene panels may include genes not associated with the condition discussed in this <italic toggle="yes">GeneReview</italic>; clinicians need to determine which multi-gene panel provides the best opportunity to identify the associated gene(s) at the most reasonable cost.</p>
            </list-item>
          </list>
          <table-wrap id="cpt1a.T.molecular_genetic_testing_used_i" position="anchor" orientation="portrait">
            <label>Table 1. </label>
            <caption>
              <p>Molecular Genetic Testing Used in Carnitine Palmitoyltransferase 1A Deficiency</p>
            </caption>
            <table frame="hsides" rules="groups">
              <thead>
                <tr>
                  <th id="hd_h_cpt1a.T.molecular_genetic_testing_used_i_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Gene&#x000a0;<sup>1</sup></th>
                  <th id="hd_h_cpt1a.T.molecular_genetic_testing_used_i_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Test Method</th>
                  <th id="hd_h_cpt1a.T.molecular_genetic_testing_used_i_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Proportion of Probands with Pathogenic Variants&#x000a0;<sup>2</sup> Detectable by This Method</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td headers="hd_h_cpt1a.T.molecular_genetic_testing_used_i_1_1_1_1" rowspan="2" valign="middle" align="left" scope="row" colspan="1">
                    <italic toggle="yes">CPT1A</italic>
                  </td>
                  <td headers="hd_h_cpt1a.T.molecular_genetic_testing_used_i_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Sequence analysis&#x000a0;<sup>3</sup><hr/></td>
                  <td headers="hd_h_cpt1a.T.molecular_genetic_testing_used_i_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">&#x0003e;90%&#x000a0;<sup>4,&#x000a0;5</sup><hr/></td>
                </tr>
                <tr>
                  <td headers="hd_h_cpt1a.T.molecular_genetic_testing_used_i_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Gene-targeted deletion/duplication analysis&#x000a0;<sup>6</sup></td>
                  <td headers="hd_h_cpt1a.T.molecular_genetic_testing_used_i_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Rare&#x000a0;<sup>7</sup></td>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn id="cpt1a.TF.1.1">
                <label>1. </label>
                <p>See <related-object source-id="gene" document-id="cpt1a" object-id="cpt1a.molgen.TA">Table A. Genes and Databases</related-object> for chromosome locus and protein.</p>
              </fn>
              <fn id="cpt1a.TF.1.2">
                <label>2. </label>
                <p>See <xref ref-type="sec" rid="cpt1a.Molecular_Genetics">Molecular Genetics</xref> for information on allelic variants detected in this gene.</p>
              </fn>
              <fn id="cpt1a.TF.1.3">
                <label>3. </label>
                <p>Sequence analysis detects variants that are benign, likely benign, of uncertain significance, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and missense, nonsense, and splice site variants; typically, exon or whole-gene deletions/duplications are not detected. For issues to consider in interpretation of sequence analysis results, click <related-object link-type="booklink" source-id="gene" document-id="app2" document-type="appendix">here</related-object>.</p>
              </fn>
              <fn id="cpt1a.TF.1.4">
                <label>4. </label>
                <p>Sequence analysis also detects the common p.Gly710Glu pathogenic variant in the Hutterite population [<xref ref-type="bibr" rid="cpt1a.REF.prasad.2001.55">Prasad et al 2001</xref>] and the p.Pro479Leu pathogenic variant in the Inuit population [<xref ref-type="bibr" rid="cpt1a.REF.brown.2001.1134">Brown et al 2001</xref>].</p>
              </fn>
              <fn id="cpt1a.TF.1.5">
                <label>5. </label>
                <p>In individuals with enzymatic confirmation of CPT1A deficiency</p>
              </fn>
              <fn id="cpt1a.TF.1.6">
                <label>6. </label>
                <p>Gene-targeted deletion/duplication analysis detects intragenic deletions or duplications. Methods that may be used include: quantitative PCR, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a gene-targeted microarray designed to detect single-exon deletions or duplications.</p>
              </fn>
              <fn id="cpt1a.TF.1.7">
                <label>7. </label>
                <p>Exon and multiexon deletions have been rarely reported [<xref ref-type="bibr" rid="cpt1a.REF.gobin.2002.179">Gobin et al 2002</xref>].</p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
          <p><bold>Carnitine palmitoyltransferase 1 (CPT 1) enzyme activity on cultured skin fibroblasts.</bold> Residual enzyme activity is 1%-5% in most individuals with CPT1A deficiency.</p>
        </sec>
      </sec>
      <sec id="cpt1a.Clinical_Characteristics">
        <title>Clinical Characteristics</title>
        <sec id="cpt1a.Clinical_Description">
          <title>Clinical Description</title>
          <p>Carnitine palmitoyltransferase I (CPT I) is a mitochondrial membrane protein that converts long-chain fatty acyl-CoA molecules to their corresponding acylcarnitine molecules. The resulting acylcarnitines are then available for transport into the mitochondrial matrix where they can undergo fatty acid oxidation. Mitochondrial fatty acid oxidation by the liver provides an alternative source of fuel when glycogen reserves are significantly reduced, most often due to fasting or other intercurrent illness. The pathway fuels ketogenesis for metabolism in peripheral tissues that cannot oxidize fatty acids.</p>
          <p>Clinical symptoms usually occur in an individual with a concurrent febrile or gastrointestinal illness when energy demands are increased. The precipitating illness may be a relatively common infectious disease, but the onset of symptoms is usually rapid and should alert the clinician to the possibility of a fatty acid oxidation defect.</p>
          <p>Carnitine palmitoyltransferase 1A (CPT1A) deficiency is a disorder of long-chain fatty acid oxidation.</p>
          <p><bold>Fetal CPT1A deficiency</bold> has been associated with acute fatty liver of pregnancy [<xref ref-type="bibr" rid="cpt1a.REF.innes.2000.43">Innes et al 2000</xref>]. A heterozygous female carrying an affected fetus is at risk of developing this obstetric complication. A number of other fetal fatty acid oxidation defects also carry a similar risk to the heterozygous mother of developing acute fatty liver of pregnancy, typically in the third trimester, prompting further investigation of the newborn for a fatty acid oxidation defect in this situation.</p>
          <p><bold>Hepatic encephalopathy.</bold> Although some neonates present with "physiologic" hypoglycemia of the newborn, most individuals with CPT1A deficiency present with fasting-induced hepatic encephalopathy in early childhood. This is a potentially fatal presentation; children who recover are at risk for recurrent episodes of life-threatening illness.</p>
          <p>Survival through infancy without symptoms has been reported; initial presentation may occur later in life with similar life-threatening acute hepatic illness. For example, death as a result of rapid-onset hepatic failure in CPT1A deficiency occurred in an individual age 17 years despite the early recognition of a fatty acid oxidation defect [<xref ref-type="bibr" rid="cpt1a.REF.brown.2001.1134">Brown et al 2001</xref>].</p>
          <p>Between episodes of metabolic decompensation, individuals appear developmentally and cognitively normal unless previous metabolic decompensation has resulted in neurologic damage.</p>
          <p>Recognition of CPT1A deficiency and initiating management to prevent lipolysis reduces the episodes of decompensation [<xref ref-type="bibr" rid="cpt1a.REF.stoler.2004.679">Stoler et al 2004</xref>, <xref ref-type="bibr" rid="cpt1a.REF.stanley.2014">Stanley et al 2014</xref>].</p>
          <p>Long-term liver damage as a result of recurring hepatosteatosis has not been reported.</p>
          <p>Some individuals with the hepatic encephalopathy phenotype have also had renal tubular acidosis.</p>
          <p>Unlike with other long-chain fatty acid oxidation defects, cardiac or skeletal muscle involvement is not common [<xref ref-type="bibr" rid="cpt1a.REF.bonnefont.2004.495">Bonnefont et al 2004</xref>, <xref ref-type="bibr" rid="cpt1a.REF.stanley.2014">Stanley et al 2014</xref>].</p>
        </sec>
        <sec id="cpt1a.GenotypePhenotype_Correlations">
          <title>Genotype-Phenotype Correlations</title>
          <p>The <xref ref-type="table" rid="cpt1a.T.selected_cpt1a_pathogenic_alleli">p.Pro479Leu</xref> pathogenic variant observed in the Inuit, which has high residual enzymatic activity (15%-20%), does not appear to cause acute hepatic failure as do the other pathogenic variants associated with the more severe phenotype [<xref ref-type="bibr" rid="cpt1a.REF.brown.2001.1134">Brown et al 2001</xref>]. However, evidence suggests that infants who are homozygous for the variant have impaired fasting tolerance [<xref ref-type="bibr" rid="cpt1a.REF.gillingham.2011.261">Gillingham et al 2011</xref>] and increased risk of infant mortality [<xref ref-type="bibr" rid="cpt1a.REF.gessner.2010.945">Gessner et al 2010</xref>]. In a study using whole-genome high-coverage sequence data of Arctic populations, this <italic toggle="yes">CPT1A</italic> variant was identified as deleterious and associated with increased infant mortality in circum-Arctic populations [<xref ref-type="bibr" rid="cpt1a.REF.clemente.2014.584">Clemente et al 2014</xref>].</p>
        </sec>
        <sec id="cpt1a.Nomenclature">
          <title>Nomenclature</title>
          <p>The disorder has been previously described as non-ketotic hypoglycemia, hepatic CPT deficiency, hepatic CPT1, and L-CPT1 deficiency.</p>
        </sec>
        <sec id="cpt1a.Prevalence">
          <title>Prevalence</title>
          <p>CPT1A deficiency caused by variants other than <xref ref-type="table" rid="cpt1a.T.selected_cpt1a_pathogenic_alleli">p.Pro479Leu</xref> appears to be very rare in the general population, with fewer than 60 affected individuals reported.</p>
          <p>Improved detection of CPT1A deficiency in the newborn period may increase the detection rate for the disorder [<xref ref-type="bibr" rid="cpt1a.REF.sim.2001.51">Sim et al 2001</xref>]. The number of non-Inuit diagnoses in the Region 4 Stork (R4S) newborn screening collaborative for 2015 was five cases, giving an estimated prevalence of 1:500,000 to 1:1,000,000 newborns [Piero Rinaldo, personal communication].</p>
          <p>The frequency of homozygosity for the p.Pro479Leu pathogenic variant is very high in the native Alaskan population (1.3:1,000 live births) when ascertained by expanded newborn screening (available through <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.epi.hss.state.ak.us/bulletins/docs/b2006_19.pdf">Alaska Division of Public Health</ext-link> [pdf]). Given the high residual enzyme activity associated with this allele, p.Pro479Leu homozygosity is generally regarded as non-pathogenic but may still be associated with increased infant mortality [<xref ref-type="bibr" rid="cpt1a.REF.clemente.2014.584">Clemente et al 2014</xref>] (see <xref ref-type="sec" rid="cpt1a.GenotypePhenotype_Correlations">Genotype-Phenotype Correlations</xref>).</p>
          <p>The carrier rate for the <xref ref-type="table" rid="cpt1a.T.selected_cpt1a_pathogenic_alleli">p.Gly710Glu</xref> pathogenic variant in the Hutterite population may be as high as 1:16 [<xref ref-type="bibr" rid="cpt1a.REF.prasad.2001.55">Prasad et al 2001</xref>].</p>
        </sec>
      </sec>
      <sec id="cpt1a.Genetically_Related_Allelic_Disord">
        <title>Genetically Related (Allelic) Disorders</title>
        <p>No phenotypes other than those discussed in this <italic toggle="yes">GeneReview</italic> are known to be associated with biallelic pathogenic variants in <italic toggle="yes">CPT1A</italic>.</p>
      </sec>
      <sec id="cpt1a.Differential_Diagnosis">
        <title>Differential Diagnosis</title>
        <p>The absence (or paucity) of ketone bodies during a period of hypoglycemia should increase suspicion for one of the disorders of fatty acid oxidation or the carnitine cycle, including carnitine palmitoyltransferase 1A (CPT1A) deficiency.</p>
        <p>Because the CPT1A enzyme is primarily expressed in liver, CPT1A deficiency is clinically more closely related to fatty acid and ketogenesis disorders with hepatic phenotypes. These include the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>
              <related-object link-type="booklink" source-id="gene" document-id="mcad" document-type="chapter">Medium-chain acyl-CoA dehydrogenase (MCAD) deficiency</related-object>
            </p>
          </list-item>
          <list-item>
            <p>3-hydroxy-3-methylglutaryl (HMG)-CoA synthase deficiency (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/605911">OMIM</ext-link>)</p>
          </list-item>
          <list-item>
            <p>HMG-CoA lyase deficiency</p>
          </list-item>
        </list>
        <p>In the absence of muscle or heart manifestations, the acute hepatic presentation of CPT1A deficiency cannot be clinically distinguished from other defects of long-chain fatty acid oxidation and conditions that present as a Reye-like illness. These include the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>
              <related-object link-type="booklink" source-id="gene" document-id="cpt2" document-type="chapter">Carnitine palmitoyltransferase II (CPT II) deficiency</related-object>
            </p>
          </list-item>
          <list-item>
            <p>Carnitine acylcarnitine translocase (CACT) deficiency (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/212138">OMIM</ext-link>)</p>
          </list-item>
          <list-item>
            <p>
              <related-object link-type="booklink" source-id="gene" document-id="vlcad" document-type="chapter">Very-long-chain acyl-CoA dehydrogenase deficiency</related-object>
            </p>
          </list-item>
          <list-item>
            <p>Mitochondrial trifunctional protein deficiency (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/609015">OMIM</ext-link>) including long-chain 3-hydroxyacyl-CoA dehydrogenase deficiency (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/609016">OMIM</ext-link>)</p>
          </list-item>
          <list-item>
            <p>
              <related-object link-type="booklink" source-id="gene" document-id="ucd-overview" document-type="chapter">Urea cycle disorders</related-object>
            </p>
          </list-item>
          <list-item>
            <p>Organic acidurias such as methylmalonic and propionic acidemia</p>
          </list-item>
          <list-item>
            <p>Disorders of oxidative phosphorylation (see <related-object link-type="booklink" source-id="gene" document-id="mt-overview" document-type="chapter">Mitochondrial Disorders Overview</related-object>)</p>
          </list-item>
          <list-item>
            <p>Disorders of gluconeogenesis (including <related-object link-type="booklink" source-id="gene" document-id="gsd1" document-type="chapter">glycogen storage disease type I</related-object>)</p>
          </list-item>
        </list>
      </sec>
      <sec id="cpt1a.Management">
        <title>Management</title>
        <sec id="cpt1a.Evaluations_Following_Initial_Diag">
          <title>Evaluations Following Initial Diagnosis</title>
          <p>To establish the extent of disease and needs of an individual diagnosed with carnitine palmitoyltransferase 1A (CPT1A) deficiency, the following evaluations are recommended:</p>
          <list list-type="bullet">
            <list-item>
              <p>In affected individuals who have profound and/or prolonged exposure to hypoglycemia: a complete neurologic evaluation to detect secondary neurologic damage</p>
            </list-item>
            <list-item>
              <p>Consultation with a clinical geneticist and/or genetic counselor</p>
            </list-item>
          </list>
        </sec>
        <sec id="cpt1a.Treatment_of_Manifestations">
          <title>Treatment of Manifestations</title>
          <p>Guidelines for the treatment of CPT1A deficiency can be found at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.newbornscreening.info/Parents/fattyaciddisorders/CPT1.html">newbornscreening.info</ext-link> and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://ghr.nlm.nih.gov/condition/carnitine-palmitoyltransferase-i-deficiency">ghr.nlm.nih.gov</ext-link>.</p>
          <p>When individuals present with acute hypoglycemia, sufficient amounts of intravenous fluid containing 10% dextrose should be provided as quickly as possible to correct hypoglycemia and to prevent lipolysis and subsequent mobilization of fatty acids into the mitochondria.</p>
          <p>Because individuals presenting with profound hypoglycemia have little to no residual hepatic glycogen, treating physicians should continue the glucose infusion beyond the time that blood glucose concentration has normalized in order to provide sufficient substrate for glycogen synthesis.</p>
          <p>A letter should be provided to affected individuals (or their parents/guardians) and involved health care providers alerting them to the potentially catastrophic metabolic crises for which these individuals are at risk and explaining the appropriate emergency treatment.</p>
        </sec>
        <sec id="cpt1a.Prevention_of_Primary_Manifestatio">
          <title>Prevention of Primary Manifestations</title>
          <p>A high-carbohydrate diet (70% of calories) that is low in fat (&#x0003c;20% of calories) is generally recommended to provide a constant supply of carbohydrate energy, particularly during illness. Restriction of dietary fat intake is somewhat controversial when affected individuals are well. If the physician chooses to recommend a low-fat diet when the affected individual is well, supplementation with essential fatty acids is necessary.</p>
          <p>Provision of approximately one third of total calories as medium-chain triglycerides is recommended during periods of illness. C6-C10 fatty acids do not require the carnitine shuttle for entry into the mitochondrion.</p>
          <p>Frequent feeding is recommended, particularly for infants, given their limited glycogen reserves. Cornstarch feedings given overnight provide a constant source of slow-release carbohydrate to prevent hypoglycemia during sleep.</p>
          <p>Older children should not fast for more than 12 hours and for a shorter time if evidence of a febrile or gastrointestinal illness exists.</p>
          <p>Adults should be aware of the risks of fasting and they and their primary care physician should be aware of the risks during surgery when both metabolic stress and fasting occur.</p>
          <p>Brief hospital admission for administration of intravenous dextrose-containing fluid should be considered in individuals with known CPT1A deficiency who are required to fast more than 12 hours because of illness or surgical or medical procedures.</p>
        </sec>
        <sec id="cpt1a.Prevention_of_Secondary_Complicati">
          <title>Prevention of Secondary Complications</title>
          <p>Prevention of hypoglycemia reduces the risk of related neurologic damage.</p>
        </sec>
        <sec id="cpt1a.Surveillance">
          <title>Surveillance</title>
          <p>At clinic appointments and during periods of reduced caloric intake and febrile illness that could precipitate metabolic decompensation, individuals with CPT1A deficiency should undergo liver function testing whether they are symptomatic or not. Tests should include liver enzymes, AST, ALT, alkaline phosphatase (ALP), and functional liver tests (including the blood-clotting tests PT and PTT).</p>
        </sec>
        <sec id="cpt1a.AgentsCircumstances_to_Avoid">
          <title>Agents/Circumstances to Avoid</title>
          <p>Prolonged fasting should be avoided, especially during a febrile or gastrointestinal illness.</p>
          <p>Potentially hepatotoxic agents such as valproate and salicylate should not be given, even though adverse effects of pharmacologic agents have not been reported in individuals with CPT1A deficiency.</p>
        </sec>
        <sec id="cpt1a.Evaluation_of_Relatives_at_Risk">
          <title>Evaluation of Relatives at Risk</title>
          <p>Because presentation in later childhood is possible, it is appropriate to evaluate each sib of a proband, regardless of age, in order to identify as early as possible those who would benefit from initiation of preventive measures.</p>
          <p>Evaluations can include:</p>
          <list list-type="bullet">
            <list-item>
              <p>Molecular genetic testing if the <italic toggle="yes">CPT1A</italic> pathogenic variants in the family are known.</p>
            </list-item>
            <list-item>
              <p>Enzyme analysis in cultured skin fibroblasts if the pathogenic variants in the family are not known.</p>
            </list-item>
          </list>
          <p>See <xref ref-type="sec" rid="cpt1a.Related_Genetic_Counseling_Issues">Genetic Counseling</xref> for issues related to testing of at-risk relatives for genetic counseling purposes.</p>
        </sec>
        <sec id="cpt1a.Pregnancy_Management">
          <title>Pregnancy Management</title>
          <p>Although data are limited, it is prudent to counsel unaffected female carriers regarding the risk for obstetric complications.</p>
          <p>Women who have had one child with CPT1A deficiency following an uneventful pregnancy remain at risk for acute fatty liver of pregnancy in subsequent pregnancies with an affected fetus.</p>
          <p>Pregnant females who are heterozygous for a <italic toggle="yes">CPT1A</italic> pathogenic variant should be monitored for acute fatty liver of pregnancy. In any pregnancies that follow identification of a child with CPT1A deficiency, liver function testing should be performed at each prenatal visit during the first two trimesters and more frequently during the third trimester when the risk for acute fatty liver of pregnancy is greatest. Management by a team comprising a maternal-fetal medicine specialist and a medical/biochemical geneticist is highly recommended.</p>
        </sec>
        <sec id="cpt1a.Therapies_Under_Investigation">
          <title>Therapies Under Investigation</title>
          <p>Search <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://clinicaltrials.gov/">ClinicalTrials.gov</ext-link> for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.</p>
        </sec>
      </sec>
      <sec id="cpt1a.Genetic_Counseling">
        <title>Genetic Counseling</title>
        <sec id="cpt1a.Mode_of_Inheritance">
          <title>Mode of Inheritance</title>
          <p>Carnitine palmitoyltransferase 1A (CPT1A) deficiency is inherited in an autosomal recessive manner.</p>
        </sec>
        <sec id="cpt1a.Risk_to_Family_Members">
          <title>Risk to Family Members</title>
          <p>
            <bold>Parents of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The parents of an affected individual are obligate heterozygotes (i.e., carriers of one <italic toggle="yes">CPT1A</italic> pathogenic variant).</p>
            </list-item>
            <list-item>
              <p>Heterozygotes (carriers) are asymptomatic. Pregnant female carriers may be at risk of developing acute fatty liver of pregnancy if the fetus has CPT1A deficiency.</p>
            </list-item>
          </list>
          <p>
            <bold>Sibs of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>At conception, each sib of an affected individual has a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier.</p>
            </list-item>
            <list-item>
              <p>Heterozygotes (carriers) are asymptomatic. Pregnant females who are heterozygous for a <italic toggle="yes">CPT1A</italic> pathogenic variant may be at risk of developing acute fatty liver of pregnancy if the fetus has CPT1A deficiency.</p>
            </list-item>
          </list>
          <p>
            <bold>Offspring of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The offspring of an individual with CPT1A deficiency are obligate heterozygotes (carriers) for a pathogenic variant in <italic toggle="yes">CPT1A</italic>.</p>
            </list-item>
            <list-item>
              <p>In populations with a high carrier rate and/or a high rate of consanguinity, it is possible that the reproductive partner of the proband may be affected or a carrier. Thus, the risk to offspring is most accurately determined after molecular genetic and/or biochemical testing of the proband's reproductive partner.</p>
            </list-item>
          </list>
          <p><bold>Other family members.</bold> Each sib of the proband's parents is at a 50% risk of being a carrier of a <italic toggle="yes">CPT1A</italic> pathogenic variant.</p>
        </sec>
        <sec id="cpt1a.Heterozygote_Carrier_Detection">
          <title>Heterozygote (Carrier) Detection</title>
          <p>Carrier testing for at-risk relatives requires prior identification of the <italic toggle="yes">CPT1A</italic> pathogenic variants in the family.</p>
        </sec>
        <sec id="cpt1a.Related_Genetic_Counseling_Issues">
          <title>Related Genetic Counseling Issues</title>
          <p>See Management, <xref ref-type="sec" rid="cpt1a.Evaluation_of_Relatives_at_Risk">Evaluation of Relatives at Risk</xref> for information on evaluating at-risk relatives for the purpose of early diagnosis and treatment.</p>
          <p>
            <bold>Family planning</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The optimal time for determination of genetic risk, clarification of carrier status, and discussion of the availability of prenatal testing is before pregnancy.</p>
            </list-item>
            <list-item>
              <p>It is appropriate to offer genetic counseling (including discussion of potential risks to offspring and reproductive options) to young adults who are affected, are carriers, or are at risk of being carriers.</p>
            </list-item>
          </list>
          <p><bold>DNA banking</bold> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of affected individuals.</p>
        </sec>
        <sec id="cpt1a.Prenatal_Testing_and_Preimplantati">
          <title>Prenatal Testing and Preimplantation Genetic Diagnosis</title>
          <p><bold>Molecular genetic testing.</bold> Once the <italic toggle="yes">CPT1A</italic> pathogenic variants have been identified in an affected family member, prenatal testing and preimplantation genetic diagnosis for a pregnancy at increased risk for CPT1A deficiency are possible options.</p>
        </sec>
      </sec>
      <sec id="cpt1a.Resources">
        <title>Resources</title>
      </sec>
      <sec id="cpt1a.Molecular_Genetics">
        <title>Molecular Genetics</title>
        <sec id="cpt1a.Molecular_Genetic_Pathogenesis">
          <title>Molecular Genetic Pathogenesis</title>
          <p>The so-called carnitine shuttle mediates transport of long-chain fatty acyl species from the cytosol into the mitochondria for energy production by &#x003b2;-oxidation. Carnitine palmitoyltransferase I (CPT I) on the outer mitochondrial membrane converts long-chain acyl-CoAs to their acylcarnitine equivalents, which are transported into the inner mitochondrial compartment by carnitine acylcarnitine translocase and then reconverted to the acyl-CoA species by CPT II at the inner mitochondrial membrane [<xref ref-type="bibr" rid="cpt1a.REF.mcgarry.1997.1">McGarry &#x00026; Brown 1997</xref>]. CPT I is thus the rate-limiting factor for entry of long-chain fatty acids into the mitochondria for &#x003b2;-oxidation.</p>
          <p>In the reduced activity of CPT I caused by biallelic pathogenic variants of <italic toggle="yes">CPT1A</italic>, fatty acids cannot enter the mitochondria for energy production (see <xref ref-type="fig" rid="cpt1a.F1">Figure 1</xref>); the result is a clinical and biochemical phenotype of fasting intolerance.</p>
          <p>Of the three CPT I family members, CPT1A is expressed in liver, kidney, leukocytes, and skin fibroblasts; CPT1B is expressed in muscle; and CPT1C is brain specific. Pathogenic variants in <italic toggle="yes">CPT1A</italic> and <italic toggle="yes">CPT1C</italic> have been associated with genetic disease. A dominantly inherited pathogenic variant in <italic toggle="yes">CPT1C</italic> has recently been associated with and is likely to be causative of spastic paraplegia 73 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/616282">OMIM</ext-link>), a condition with no similarity to CPT1A deficiency [<xref ref-type="bibr" rid="cpt1a.REF.rinaldi.2015.561">Rinaldi et al 2015</xref>].</p>
          <p><bold>Gene structure.</bold>
<italic toggle="yes">CPT1A</italic> spans more than 60 kb of genomic DNA, of which 18 exons (2-19) are transcribed. For a detailed summary of gene and protein information, see <related-object source-id="gene" document-id="cpt1a" object-id="cpt1a.molgen.TA">Table A</related-object>, <bold>Gene</bold>.</p>
          <p><bold>Pathogenic allelic variants.</bold> Outside the Hutterite and Inuit populations, all pathogenic variants characterized to date have been within single families (see <inline-supplementary-material xmlns:xlink="http://www.w3.org/1999/xlink" xlink:title="media" xlink:href="cpt1a-Table2.pdf" content-type="local-data">Table 2</inline-supplementary-material> [pdf]) and many span the catalytic region. These include 15 pathogenic missense variants (listed in <xref ref-type="table" rid="cpt1a.T.selected_cpt1a_pathogenic_alleli">Table 3</xref>) as well as insertions and deletions [<xref ref-type="bibr" rid="cpt1a.REF.gobin.2002.179">Gobin et al 2002</xref>, <xref ref-type="bibr" rid="cpt1a.REF.bonnefont.2004.495">Bonnefont et al 2004</xref>, <xref ref-type="bibr" rid="cpt1a.REF.stoler.2004.679">Stoler et al 2004</xref>, <xref ref-type="bibr" rid="cpt1a.REF.korman.2005.337">Korman et al 2005</xref>]. Approximately 50% of individuals characterized to date are homozygous for a unique pathogenic variant.</p>
          <table-wrap id="cpt1a.T.selected_cpt1a_pathogenic_alleli" position="anchor" orientation="portrait">
            <label>Table 3. </label>
            <caption>
              <p>Selected <italic toggle="yes">CPT1A</italic> Pathogenic Allelic Variants</p>
            </caption>
            <table frame="hsides" rules="groups">
              <thead>
                <tr>
                  <th id="hd_h_cpt1a.T.selected_cpt1a_pathogenic_alleli_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">DNA Nucleotide Change</th>
                  <th id="hd_h_cpt1a.T.selected_cpt1a_pathogenic_alleli_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Protein Amino Acid Change<break/>(Alias&#x000a0;<sup>1</sup>)</th>
                  <th id="hd_h_cpt1a.T.selected_cpt1a_pathogenic_alleli_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Reference Sequences</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td headers="hd_h_cpt1a.T.selected_cpt1a_pathogenic_alleli_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.96T&#x0003e;G<hr/></td>
                  <td headers="hd_h_cpt1a.T.selected_cpt1a_pathogenic_alleli_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Tyr32Ter<hr/></td>
                  <td headers="hd_h_cpt1a.T.selected_cpt1a_pathogenic_alleli_1_1_1_3" rowspan="22" valign="middle" align="left" colspan="1">
                    <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/nuccore/NM_001876.3">NM_001876.3</ext-link>
                    <break/>
                    <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/protein/NP_001867.2">NP_001867.2</ext-link>
                  </td>
                </tr>
                <tr>
                  <td headers="hd_h_cpt1a.T.selected_cpt1a_pathogenic_alleli_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.298C&#x0003e;T<hr/></td>
                  <td headers="hd_h_cpt1a.T.selected_cpt1a_pathogenic_alleli_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Gln100Ter<hr/></td>
                </tr>
                <tr>
                  <td headers="hd_h_cpt1a.T.selected_cpt1a_pathogenic_alleli_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.367C&#x0003e;T<hr/></td>
                  <td headers="hd_h_cpt1a.T.selected_cpt1a_pathogenic_alleli_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Arg123Cys<hr/></td>
                </tr>
                <tr>
                  <td headers="hd_h_cpt1a.T.selected_cpt1a_pathogenic_alleli_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.478C&#x0003e;T<hr/></td>
                  <td headers="hd_h_cpt1a.T.selected_cpt1a_pathogenic_alleli_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Arg160Ter<hr/></td>
                </tr>
                <tr>
                  <td headers="hd_h_cpt1a.T.selected_cpt1a_pathogenic_alleli_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.912C&#x0003e;G<hr/></td>
                  <td headers="hd_h_cpt1a.T.selected_cpt1a_pathogenic_alleli_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Cys304Trp<hr/></td>
                </tr>
                <tr>
                  <td headers="hd_h_cpt1a.T.selected_cpt1a_pathogenic_alleli_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.941C&#x0003e;T<hr/></td>
                  <td headers="hd_h_cpt1a.T.selected_cpt1a_pathogenic_alleli_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Thr314Ile<hr/></td>
                </tr>
                <tr>
                  <td headers="hd_h_cpt1a.T.selected_cpt1a_pathogenic_alleli_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.946C&#x0003e;G<hr/></td>
                  <td headers="hd_h_cpt1a.T.selected_cpt1a_pathogenic_alleli_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Arg316Gly<hr/></td>
                </tr>
                <tr>
                  <td headers="hd_h_cpt1a.T.selected_cpt1a_pathogenic_alleli_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.1027T&#x0003e;G<hr/></td>
                  <td headers="hd_h_cpt1a.T.selected_cpt1a_pathogenic_alleli_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Phe343Val<hr/></td>
                </tr>
                <tr>
                  <td headers="hd_h_cpt1a.T.selected_cpt1a_pathogenic_alleli_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.1069C&#x0003e;T<hr/></td>
                  <td headers="hd_h_cpt1a.T.selected_cpt1a_pathogenic_alleli_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Arg357Trp<hr/></td>
                </tr>
                <tr>
                  <td headers="hd_h_cpt1a.T.selected_cpt1a_pathogenic_alleli_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.1079A&#x0003e;G<hr/></td>
                  <td headers="hd_h_cpt1a.T.selected_cpt1a_pathogenic_alleli_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Glu360Gly<hr/></td>
                </tr>
                <tr>
                  <td headers="hd_h_cpt1a.T.selected_cpt1a_pathogenic_alleli_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.1241C&#x0003e;T<hr/></td>
                  <td headers="hd_h_cpt1a.T.selected_cpt1a_pathogenic_alleli_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Ala414Val<hr/></td>
                </tr>
                <tr>
                  <td headers="hd_h_cpt1a.T.selected_cpt1a_pathogenic_alleli_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.1361A&#x0003e;G<hr/></td>
                  <td headers="hd_h_cpt1a.T.selected_cpt1a_pathogenic_alleli_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Asp454Gly<hr/></td>
                </tr>
                <tr>
                  <td headers="hd_h_cpt1a.T.selected_cpt1a_pathogenic_alleli_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.1395G&#x0003e;T<hr/></td>
                  <td headers="hd_h_cpt1a.T.selected_cpt1a_pathogenic_alleli_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Gly465Trp<hr/></td>
                </tr>
                <tr>
                  <td headers="hd_h_cpt1a.T.selected_cpt1a_pathogenic_alleli_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.1425G&#x0003e;A<hr/></td>
                  <td headers="hd_h_cpt1a.T.selected_cpt1a_pathogenic_alleli_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Trp475Ter<hr/></td>
                </tr>
                <tr>
                  <td headers="hd_h_cpt1a.T.selected_cpt1a_pathogenic_alleli_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.1436C&#x0003e;T<hr/></td>
                  <td headers="hd_h_cpt1a.T.selected_cpt1a_pathogenic_alleli_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Pro479Leu<hr/></td>
                </tr>
                <tr>
                  <td headers="hd_h_cpt1a.T.selected_cpt1a_pathogenic_alleli_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.1451T&#x0003e;C<hr/></td>
                  <td headers="hd_h_cpt1a.T.selected_cpt1a_pathogenic_alleli_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Leu484Pro<hr/></td>
                </tr>
                <tr>
                  <td headers="hd_h_cpt1a.T.selected_cpt1a_pathogenic_alleli_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.1493A&#x0003e;G<hr/></td>
                  <td headers="hd_h_cpt1a.T.selected_cpt1a_pathogenic_alleli_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Tyr498Cys<hr/></td>
                </tr>
                <tr>
                  <td headers="hd_h_cpt1a.T.selected_cpt1a_pathogenic_alleli_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.1494T&#x0003e;A<hr/></td>
                  <td headers="hd_h_cpt1a.T.selected_cpt1a_pathogenic_alleli_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Tyr498Ter<hr/></td>
                </tr>
                <tr>
                  <td headers="hd_h_cpt1a.T.selected_cpt1a_pathogenic_alleli_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.1600delC<hr/></td>
                  <td headers="hd_h_cpt1a.T.selected_cpt1a_pathogenic_alleli_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Leu534Ter<break/>(Leu534fsTer)<hr/></td>
                </tr>
                <tr>
                  <td headers="hd_h_cpt1a.T.selected_cpt1a_pathogenic_alleli_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.1737C&#x0003e;A<hr/></td>
                  <td headers="hd_h_cpt1a.T.selected_cpt1a_pathogenic_alleli_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Tyr579Ter<hr/></td>
                </tr>
                <tr>
                  <td headers="hd_h_cpt1a.T.selected_cpt1a_pathogenic_alleli_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.2126G&#x0003e;A<hr/></td>
                  <td headers="hd_h_cpt1a.T.selected_cpt1a_pathogenic_alleli_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Gly709Glu<hr/></td>
                </tr>
                <tr>
                  <td headers="hd_h_cpt1a.T.selected_cpt1a_pathogenic_alleli_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.2129G&#x0003e;A</td>
                  <td headers="hd_h_cpt1a.T.selected_cpt1a_pathogenic_alleli_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Gly710Glu</td>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn>
                <p>Note on variant classification: Variants listed in the table have been provided by the authors. <italic toggle="yes">GeneReviews</italic> staff have not independently verified the classification of variants.</p>
              </fn>
              <fn>
                <p>Note on nomenclature: <italic toggle="yes">GeneReviews</italic> follows the standard naming conventions of the Human Genome Variation Society (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://varnomen.hgvs.org/">varnomen.hgvs.org</ext-link>). See <related-object link-type="booklink" source-id="gene" document-id="app3" document-type="appendix">Quick Reference</related-object> for an explanation of nomenclature.</p>
              </fn>
              <fn id="cpt1a.TF.3.1">
                <label>1. </label>
                <p>Variant designation that does not conform to current naming conventions</p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
          <p><bold>Normal gene product.</bold>
<italic toggle="yes">CPT1A</italic> encodes a 773-amino acid polypeptide, which is expressed in liver, kidney, leukocytes, and skin fibroblasts. Two transmembrane domains exist and both the N and C termini are likely to be in the cytosolic compartment.</p>
          <p><bold>Abnormal gene product.</bold> Immunoblot analysis suggests that most of the pathogenic variants result in very low to undetectable enzymatic activity and no detectable protein product [<xref ref-type="bibr" rid="cpt1a.REF.brown.2001.1134">Brown et al 2001</xref>, <xref ref-type="bibr" rid="cpt1a.REF.gobin.2002.179">Gobin et al 2002</xref>].</p>
          <p>The p.Pro479Leu variant results in high residual enzyme activity and a detectable protein of normal size and amount on western blot analysis. It is believed that the product of the p.Pro479Leu allele affects malonyl-CoA interaction with CPT1A.</p>
        </sec>
      </sec>
      <sec id="cpt1a.References">
        <title>References</title>
        <sec id="cpt1a.Literature_Cited">
          <title>Literature Cited</title>
          <ref-list id="cpt1a.Literature_Cited.reflist0">
            <ref id="cpt1a.REF.bonnefont.2004.495">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Bonnefont</surname>
                    <given-names>JP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Djouadi</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Prip-Buus</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gobin</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Munnich</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bastin</surname>
                    <given-names>J</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Carnitine palmitoyltransferases 1 and 2: biochemical, molecular and medical aspects.</article-title>
                <source>Mol Aspects Med</source>
                <volume>25</volume>
                <fpage>495</fpage>
                <lpage>520</lpage>
                <pub-id pub-id-type="pmid">15363638</pub-id>
              </element-citation>
            </ref>
            <ref id="cpt1a.REF.brown.2001.1134">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Brown</surname>
                    <given-names>NF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mullur</surname>
                    <given-names>RS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Subramanian</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Esser</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bennett</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Saudubray</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Feigenbaum</surname>
                    <given-names>AS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kobari</surname>
                    <given-names>JA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Macleod</surname>
                    <given-names>PM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McGarry</surname>
                    <given-names>JD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cohen</surname>
                    <given-names>JC</given-names>
                  </name>
                </person-group>
                <year>2001</year>
                <article-title>Molecular characterization of L-CPT I deficiency in six patients: insights into function of the native enzyme.</article-title>
                <source>J Lipid Res</source>
                <volume>42</volume>
                <fpage>1134</fpage>
                <lpage>42</lpage>
                <pub-id pub-id-type="pmid">11441142</pub-id>
              </element-citation>
            </ref>
            <ref id="cpt1a.REF.clemente.2014.584">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Clemente</surname>
                    <given-names>FJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cardona</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Inchley</surname>
                    <given-names>CE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Peter</surname>
                    <given-names>BM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jacobs</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pagani</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lawson</surname>
                    <given-names>DJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Antao</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vicente</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mitt</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>DeGeorgio</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Faltyskova</surname>
                    <given-names>Z</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Xue</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ayub</surname>
                    <given-names>Q</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Szpak</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Magi</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eriksson</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Manica</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Raghavan</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rasmussen</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rasmussen</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Willersley</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vidal-Puig</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tyler-Smith</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Villems</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nielson</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Metspalu</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Malyarchuk</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Derenko</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kivisild</surname>
                    <given-names>T</given-names>
                  </name>
                </person-group>
                <year>2014</year>
                <article-title>A selective sweep of a deleterious mutation in <italic toggle="yes">CPT1A</italic> in Arctic populations.</article-title>
                <source>Amer J Hum Genet</source>
                <volume>95</volume>
                <fpage>584</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">25449608</pub-id>
              </element-citation>
            </ref>
            <ref id="cpt1a.REF.collins.2010.200">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Collins</surname>
                    <given-names>SA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sinclair</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McIntosh</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bamforth</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Thompson</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sobol</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Osborne</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Corriveau</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Santos</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hanley</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Greenberg</surname>
                    <given-names>CR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vallance</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Arbour</surname>
                    <given-names>L</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>Carnitine palmitoyltransferase 1A(CPT1A) P479L prevalence in live newborns in Yukon, Northwest Territories, and Nanavut</article-title>
                <source>Mol Genet Metab.</source>
                <volume>101</volume>
                <fpage>200</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">20696606</pub-id>
              </element-citation>
            </ref>
            <ref id="cpt1a.REF.fingerhut.2001.1763">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Fingerhut</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Roschinger</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Muntau</surname>
                    <given-names>AC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dame</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kreischer</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Arnecke</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Superti-Furga</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Troxler</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Liebl</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Olgemoller</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Roscher</surname>
                    <given-names>AA</given-names>
                  </name>
                </person-group>
                <year>2001</year>
                <article-title>Hepatic carnitine palmitoyltransferase I deficiency: acylcarnitine profiles in blood spots are highly specific.</article-title>
                <source>Clin Chem</source>
                <volume>47</volume>
                <fpage>1763</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">11568084</pub-id>
              </element-citation>
            </ref>
            <ref id="cpt1a.REF.gessner.2010.945">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Gessner</surname>
                    <given-names>BD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gillingham</surname>
                    <given-names>MB.</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Birch</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wood</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Koeller</surname>
                    <given-names>DM</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>Evidence for an association between infant mortality and a carnitine palmitoyltransferase 1A genetic variant.</article-title>
                <source>Pediatrics</source>
                <volume>126</volume>
                <fpage>945</fpage>
                <lpage>51</lpage>
                <pub-id pub-id-type="pmid">20937660</pub-id>
              </element-citation>
            </ref>
            <ref id="cpt1a.REF.gillingham.2011.261">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Gillingham</surname>
                    <given-names>MB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hirschfeld</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lowe</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Matern</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shoemaker</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lambert</surname>
                    <given-names>WE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Koeller</surname>
                    <given-names>DM</given-names>
                  </name>
                </person-group>
                <article-title>Impaired fasting tolerance among Alaska native children with a common carnitine palmitoyltransferase 1A sequence variant.</article-title>
                <source>Mol Genet Metab.</source>
                <year>2011</year>
                <volume>104</volume>
                <fpage>261</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">21763168</pub-id>
              </element-citation>
            </ref>
            <ref id="cpt1a.REF.gobin.2002.179">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Gobin</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bonnefont</surname>
                    <given-names>JP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Prip-Buus</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mugnier</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ferrec</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Demaugre</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Saudubray</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rostane</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Djouadi</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wilcox</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cederbaum</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Haas</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nyhan</surname>
                    <given-names>WL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Green</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gray</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Girard</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Thuillier</surname>
                    <given-names>L</given-names>
                  </name>
                </person-group>
                <year>2002</year>
                <article-title>Organization of the human liver carnitine palmitoyltransferase 1 gene (CPT1A) and identification of novel mutations in hypoketotic hypoglycaemia.</article-title>
                <source>Hum Genet</source>
                <volume>111</volume>
                <fpage>179</fpage>
                <lpage>89</lpage>
                <pub-id pub-id-type="pmid">12189492</pub-id>
              </element-citation>
            </ref>
            <ref id="cpt1a.REF.innes.2000.43">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Innes</surname>
                    <given-names>AM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Seargeant</surname>
                    <given-names>LE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Balachandra</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Roe</surname>
                    <given-names>CR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wanders</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ruiter</surname>
                    <given-names>JP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Casiro</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Grewar</surname>
                    <given-names>DA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Greenberg</surname>
                    <given-names>CR</given-names>
                  </name>
                </person-group>
                <article-title>Hepatic carnitine palmitoyltransferase I deficiency presenting as maternal illness in pregnancy.</article-title>
                <source>Pediatr Res.</source>
                <year>2000</year>
                <volume>47</volume>
                <fpage>43</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">10625081</pub-id>
              </element-citation>
            </ref>
            <ref id="cpt1a.REF.korman.2005.337">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Korman</surname>
                    <given-names>SH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Waterham</surname>
                    <given-names>HR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gutman</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jakobs</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wanders</surname>
                    <given-names>RJ</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Novel metabolic and molecular findings in hepatic carnitine palmitoyltransferase I deficiency.</article-title>
                <source>Mol Genet Metab</source>
                <volume>86</volume>
                <fpage>337</fpage>
                <lpage>43</lpage>
                <pub-id pub-id-type="pmid">16146704</pub-id>
              </element-citation>
            </ref>
            <ref id="cpt1a.REF.mcgarry.1997.1">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>McGarry</surname>
                    <given-names>JD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brown</surname>
                    <given-names>NF</given-names>
                  </name>
                </person-group>
                <year>1997</year>
                <article-title>The mitochondrial carnitine palmitoyltransferase system. From concept to molecular analysis.</article-title>
                <source>Eur J Biochem</source>
                <volume>244</volume>
                <fpage>1</fpage>
                <lpage>14</lpage>
                <pub-id pub-id-type="pmid">9063439</pub-id>
              </element-citation>
            </ref>
            <ref id="cpt1a.REF.park.2006.1090">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Park</surname>
                    <given-names>JY</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Narayan</surname>
                    <given-names>SB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bennett</surname>
                    <given-names>MJ</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Molecular assay for detection of the common carnitine palmitoyltransferase 1A 1436(C&#x0003e;T) mutation.</article-title>
                <source>Clin Chem Lab Med</source>
                <volume>44</volume>
                <fpage>1090</fpage>
                <lpage>1</lpage>
                <pub-id pub-id-type="pmid">16958601</pub-id>
              </element-citation>
            </ref>
            <ref id="cpt1a.REF.prasad.2001.55">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Prasad</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Johnson</surname>
                    <given-names>JP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bonnefont</surname>
                    <given-names>JP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dilling</surname>
                    <given-names>LA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Innes</surname>
                    <given-names>AM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Haworth</surname>
                    <given-names>JC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Beischel</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Thuillier</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Prip-Buus</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Singal</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Thompson</surname>
                    <given-names>JR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Prasad</surname>
                    <given-names>AN</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Buist</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Greenberg</surname>
                    <given-names>CR</given-names>
                  </name>
                </person-group>
                <year>2001</year>
                <article-title>Hepatic carnitine palmitoyl transferase 1 (CPT1 A) deficiency in North American Hutterites (Canadian and American): evidence for a founder effect and results of a pilot study on a DNA-based newborn screening program.</article-title>
                <source>Mol Genet Metab</source>
                <volume>73</volume>
                <fpage>55</fpage>
                <lpage>63</lpage>
                <pub-id pub-id-type="pmid">11350183</pub-id>
              </element-citation>
            </ref>
            <ref id="cpt1a.REF.rajakumar.2009.1223">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Rajakumar</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ban</surname>
                    <given-names>MR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cao</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Young</surname>
                    <given-names>TK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bjerregaard</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hegele</surname>
                    <given-names>RA</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>Carnitine palmitoyltransferase 1A polymorphism P479L is common in Greenland Inuit and is associated with elevated plasma apolipoprotein A-1.</article-title>
                <source>J Lipid Res</source>
                <volume>50</volume>
                <fpage>1223</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">19181627</pub-id>
              </element-citation>
            </ref>
            <ref id="cpt1a.REF.rinaldi.2015.561">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Rinaldi</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schmidt</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Situ</surname>
                    <given-names>AJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Johnson</surname>
                    <given-names>JO</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lee</surname>
                    <given-names>PR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chen</surname>
                    <given-names>KL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bott</surname>
                    <given-names>LC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fad&#x000f3;</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Harmison</surname>
                    <given-names>GH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Parodi</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Grunseich</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Renvois&#x000e9;</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Biesecker</surname>
                    <given-names>LG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>De Michele</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Santorelli</surname>
                    <given-names>FM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Filla</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stevanin</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>D&#x000fc;rr</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brice</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Casals</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Traynor</surname>
                    <given-names>BJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Blackstone</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ulmer</surname>
                    <given-names>TS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fischbeck</surname>
                    <given-names>KH</given-names>
                  </name>
                </person-group>
                <article-title>Mutation in CPT1C Associated With Pure Autosomal Dominant Spastic Paraplegia.</article-title>
                <source>JAMA Neurol.</source>
                <year>2015</year>
                <volume>72</volume>
                <fpage>561</fpage>
                <lpage>70</lpage>
                <pub-id pub-id-type="pmid">25751282</pub-id>
              </element-citation>
            </ref>
            <ref id="cpt1a.REF.sim.2001.51">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Sim</surname>
                    <given-names>KG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wiley</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Carpenter</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wilcken</surname>
                    <given-names>B</given-names>
                  </name>
                </person-group>
                <year>2001</year>
                <article-title>Carnitine palmitoyltransferase I deficiency in neonate identified by dried blood spot free carnitine and acylcarnitine profile.</article-title>
                <source>J Inherit Metab Dis</source>
                <volume>24</volume>
                <fpage>51</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">11286383</pub-id>
              </element-citation>
            </ref>
            <ref id="cpt1a.REF.stanley.2014">
              <mixed-citation publication-type="book">Stanley CA, Palmieri F, Bennett MJ. Disorders of the mitochondrial carnitine shuttle. In: Valle D, Beaudet AL, Vogelstein B, Kinzler KW, Antonarakis SE, Ballabio A, Gibson K, Mitchell G, eds <italic toggle="yes">The Online Metabolic and Molecular Bases of Inherited Disease (OMMBID)</italic>. Chap 101a. New York, NY: McGraw-Hill; 2014. Available <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://ommbid.mhmedical.com/ommbid-index.aspx">online</ext-link>.</mixed-citation>
            </ref>
            <ref id="cpt1a.REF.stoler.2004.679">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Stoler</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sabry</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hanley</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hoppel</surname>
                    <given-names>CL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shih</surname>
                    <given-names>VE</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Successful long-term treatment of hepatic carnitine palmitoyltransferase I deficiency and a novel mutation.</article-title>
                <source>J Inherit Metab Dis</source>
                <volume>27</volume>
                <fpage>679</fpage>
                <lpage>84</lpage>
                <pub-id pub-id-type="pmid">15669684</pub-id>
              </element-citation>
            </ref>
          </ref-list>
        </sec>
        <sec id="cpt1a.Suggested_Reading">
          <title>Suggested Reading</title>
          <ref-list id="cpt1a.Suggested_Reading.reflist0">
            <ref id="cpt1a.REF.longo.2006.77">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Longo</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Amat di San Filippo</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pasquali</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Disorders of carnitine transport and the carnitine cycle.</article-title>
                <source>Am J Med Genet C Semin Med Genet</source>
                <volume>142C</volume>
                <fpage>77</fpage>
                <lpage>85</lpage>
                <pub-id pub-id-type="pmid">16602102</pub-id>
              </element-citation>
            </ref>
            <ref id="cpt1a.REF.rinaldo.2002.477">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Rinaldo</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Matern</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bennett</surname>
                    <given-names>MJ</given-names>
                  </name>
                </person-group>
                <year>2002</year>
                <article-title>Fatty acid oxidation disorders.</article-title>
                <source>Annu Rev Physiol</source>
                <volume>64</volume>
                <fpage>477</fpage>
                <lpage>502</lpage>
                <pub-id pub-id-type="pmid">11826276</pub-id>
              </element-citation>
            </ref>
            <ref id="cpt1a.REF.strauss.2009">
              <mixed-citation publication-type="book">Strauss AW, Andresen BS, Bennett MJ. Mitochondrial fatty acid oxidation defects. In: Sarafoglou K, Hoffmann GF, Roth KS, eds. <italic toggle="yes">Pediatric Endocrinology and Inborn Errors of Metabolism</italic>. New York, NY: McGraw-Hill; 2009.</mixed-citation>
            </ref>
          </ref-list>
        </sec>
      </sec>
      <sec id="cpt1a.Chapter_Notes">
        <title>Chapter Notes</title>
        <sec id="cpt1a.Author_History">
          <title>Author History</title>
          <p>Michael J Bennett, PhD, FRCPath, DABCC (2005-present)Srinivas B Narayan, PhD, DABCC; Children&#x02019;s Hospital of Philadelphia (2005-2013)Avni B Santani, PhD, FACMG (2005-present)</p>
        </sec>
        <sec id="cpt1a.Revision_History">
          <title>Revision History</title>
          <list list-type="bullet">
            <list-item>
              <p>17 March 2016 (ma) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>7 September 2010 (me) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>24 March 2009 (cd) Revision: deletion/duplication analysis available clinically</p>
            </list-item>
            <list-item>
              <p>24 September 2007 (me) Comprehensive update posted to live Web site</p>
            </list-item>
            <list-item>
              <p>27 July 2005 (ca) Review posted to live Web site</p>
            </list-item>
            <list-item>
              <p>14 January 2005 (mb) Original submission</p>
            </list-item>
          </list>
        </sec>
      </sec>
      <sec sec-type="figs-and-tables">
        <title/>
        <fig position="float" id="cpt1a.F1" orientation="portrait">
          <label>Figure 1. </label>
          <caption>
            <p>The carnitine shuttleAcyl-CoAs are converted to acylcarnitines by carnitine palmitoyltransferase 1, translocated into the mitochondrial matrix by carnitine:acylcarnitine translocase, and reconverted to acyl-CoAs and free carnitine by carnitine palmitoyltransferase 2.</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="cpt1a-Image001" position="anchor" orientation="portrait"/>
        </fig>
      </sec>
    </body>
  </book-part>
</book-part-wrapper>
